Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...
RICHMOND, Va.--(BUSINESS WIRE)--Please replace the release dated March 2, 2022, with the following corrected version due to multiple revisions. The updated release ...
SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART ® ...
Diabetes patients have long relied on complex glucagon kits to treat hypoglycemia. Late last summer, Xeris Pharmaceuticals aimed to change that with the first FDA-approved prefilled syringe. Now, its ...
DUBLIN--(BUSINESS WIRE)--The "Epinephrine Auto-Injector Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The Global Epinephrine Auto-Injector ...
ZURICH, June 28 (Reuters) - Idorsia (IDIA.S), opens new tab is launching a late-stage trial of its experimental heart-attack drug selatogrel that the Swiss company hopes will become what it describes ...
Major factors driving the growth of this market include growing prevalence of chronic disease, increasing incidence of communicable disease due to needle stick injuries, rising demand for biosimilars ...
Richmond, Virginia, May 15, 2025 (GLOBE NEWSWIRE) -- New findings from a retrospective analysis of U.S. commercial claims data indicate that patients prescribed AUVI-Q ® (epinephrine injection, USP) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback